Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 16Genitourinary 12Breast 10Lymphoid 8CNS 8Other hematologic neoplasm 5Gynecologic 5Thoracic 4Tumor-Agnostic 2Sarcoma 2Head & Neck 2Endocrine 2Plasma cell 1Myeloid 1Dermatologic 1

Conditions

Carcinoma, Neuroendocrine 2

Interventions

lutetium Lu 177 dotatate 30Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7X-Rays 6Etoposide 6Capecitabine 6surufatinib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Magnetic Resonance Imaging × Endocrine × 1 year × Clear all
NCT07458906 2026-03-09

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

The First Affiliated Hospital of Xiamen University

Phase NA Recruiting
60 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT01879657 2025-08-06

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Radio Isotope Therapy of America

Phase NA Completed
169 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡